Status:
UNKNOWN
Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function
Lead Sponsor:
West China Hospital
Conditions:
Coronary Heart Disease
Essential Hypertension
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
The Impact of Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension
Detailed Description
Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension.We can accorand the pwv ,IMT and MDA to assess the impact of heart...
Eligibility Criteria
Inclusion
- coronary heart disease，primary hypertension， -
Exclusion
- secondary hypertension，diabetes mellitus，chronic renal disease，cardiac insufficiency
- \-
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01825759
Start Date
January 1 2013
End Date
December 1 2014
Last Update
April 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China